How to Keep HIV Cure-Related Trials Ethical: The Benefit/Risk Ratio Challenge

JME Blog, 20 February 2017
Author: Nir Eyal
“While high or unknown risks are a mainstay of early-phase trials in areas like cancer research, cure study participants typically have a safe and efficacious alternative to those risks: remaining on antiretrovirals. Can we justify asking patients who are doing well on antiretrovirals to accept the risk and uncertainty of many HIV cure-related trials? If we cannot, we might need to give up on the hope of curing HIV, or of achieving controlled remission.”
Find article here.